Unlock instant, AI-driven research and patent intelligence for your innovation.

Method for detection or treatment of graft versus host disease

a graft-versus-host disease and reagent technology, applied in the field of graft-versus-host disease detection or treatment, can solve the problems of unavoidable genetic background and environment artifacts, new therapeutic methods are needed, and the graft-versus-host disease (gvhd) remains a major complication, and achieves accurate diagnosis.

Inactive Publication Date: 2010-07-22
SAPPORO MEDICAL UNIVERSITY
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides a method and reagent for diagnosis of GVHD, and a method and pharmaceutical composition for treating GVHD. The inventors discovered that the expression level of CCL8 is significantly higher in GVHD, and there is a correlation between the expression level of CCL8 and the manifestation of clinical signs and course of GVHD. The invention provides a reliable and accurate diagnosis of GVHD through measuring the level of CCL8 protein in a sample obtained from a human or animal subject. The invention also allows treatment of GVHD in patients resistant to existing therapeutic methods.

Problems solved by technology

Post-transplantation immunosuppression therapy has made considerable progress in the last 20 years, but graft-versus-host disease (GVHD) continues to be a major, life-threatening post-transplantation complication.
Moreover, current therapeutic methods do not always result in a cure, and the development of new therapeutic methods is needed.
In tests using human clinical samples, however, artifacts related to genetic background and the environment are unavoidable, and this has confounded the discovery of a new biomarker.
There have been no reports of the discovery of a useful marker based on biochemical methods including proteomic analysis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for detection or treatment of graft versus host disease
  • Method for detection or treatment of graft versus host disease
  • Method for detection or treatment of graft versus host disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

Bone Marrow Transplantation (BMT)

[0063]Acute GVHD was induced in mice via allogeneic bone marrow transplantation. BALB / c (H-2d) mice were used as the recipients, C57BL / 6 (H-2b) mice were used as the allogeneic BMT donors, and BALB / c (H-2d) mice were used as the syngeneic BMT donors. All mice were 7 to 12 weeks old (Sankyo Labo Service corporation, Japan).

[0064]On the day of BMT, the donor mice were sacrificed by cervical dislocation. Donor bone marrow cells were collected by flushing the shaft of the femur and tibia. The cells were placed in modified Eagle's medium containing 2% fetal calf serum / 1% penicillin-streptomycin, and prepared as a single cell suspension. The cells were rinsed with RPMI 1640 medium and resuspended in that same medium. The bone marrow cell inoculum was prepared to contain 2×107 bone marrow cells / 200 μL for allogeneic BMT and 1×106 bone marrow cells / 100 μL for syngeneic BMT.

[0065]The recipient BALB / c mice were raised on acidic water for at least 7 days before...

example 2

SELDI Protein Chip Array Analysis

[0073]To 10 μL of each plasma sample was added 20 μL of a solution comprising 9 mol / L urea and 10 g / L CHAPS in Tris-HCl (pH 7.4). The mixture was mixed for 15 min at 4° C. with a vortex mixer, and was then diluted to 1:40 in Tris-HCl. Eight-spot immobilized metal affinity capture arrays (IMAC-30) were activated with 50 mmol / L CuSO4. Diluted samples (50 μL) were applied to each spot of the protein chip array, and incubated for 1 h on a shaker. After washed with the same Tris-HCl, the chip was gently rinsed with water, and 0.5 μL of saturated sinapinic acid (SPA) was applied twice to each spot, and then air-dried. The mass / charge (m / z) spectra of the proteins bound to the chelated metal were measured using a Ciphergen Protein Biology System II Time-Of-Flight mass spectrometer (PBS II, Ciphergen Biosystems, Inc.) The data were calculated by averaging 65 laser shots obtained at a laser intensity of 200 and a detector sensitivity of 8.

[0074]Statistical An...

example 3

Separation of Proteins

[0084]The three most abundant proteins in the plasma (albumin, IgG, transferrin) were removed from the pooled plasma sample by immunodepletion chromatography (Multiple Affinity Removal Column MS-3, 4.6 mm ID×50 mm; Agilent). A 5-fold dilution of 50 μL of plasma in Buffer A (Agilent) was prepared and injected into the immunodepletion column. The flow-through fractions were collected and further separated by high-performance liquid chromatography (HPLC). The separation column used in HPLC was an Inertsil™ Ph column (5 μm, 4.6 mm ID×150 mm; GL Sciences, Japan). The elution gradient profile was as follows: (1) Elution solvent A: 2% ACN / 0.1% TFA, solvent B: 80% ACN / 0.1% TFA; (2) Linear gradient: 0 to 100% for solvent B for 50 min; flow rate 1.0 mL / min.

[0085]The fractions were collected at 30 sec intervals, 2 μL of each fraction was applied to an Au chip (Cipheragen), processed with an SPA matrix, and the composition of each fraction was monitored by SELDI-TOF MS. Th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
massaaaaaaaaaa
massaaaaaaaaaa
massaaaaaaaaaa
Login to View More

Abstract

Disclosed is a method of diagnosing graft-versus-host disease, comprising measuring the level of CCL8 protein in a sample obtained from a subject as an indicator for the diagnosis or course of graft-versus-host disease. Also a diagnostic reagent for graft-versus-host disease comprising an anti-CCL8 antibody is disclosed. The method of the present invention enables diagnosis of the onset of graft-versus-host disease and monitoring of the progress, in particular, differential diagnosis between graft-versus-host disease and an infectious disease. The present invention also provides a method for treating graft-versus-host disease utilizing the anti-CCL8 antibody.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]The present invention claims priority based on Japanese Patent Application No. 2007-165547 (filed on 22 Jun. 2007), the contents of which are hereby incorporated by reference in its entirety.TECHNICAL FIELD[0002]The present invention relates to a method and reagent for diagnosis of graft-versus-host disease, as well as a method and a pharmaceutical composition for treating graft-versus-host disease.BACKGROUND ART[0003]Hematopoietic stem cell transplantation (HSCT) is a therapy where hematopoietic stem cells from another individual is transplanted into a patient to restore hematopoiesis and immune function, and it has been established as a mode of therapy in a broad range of blood, tumor, metabolism, and immune diseases. Post-transplantation immunosuppression therapy has made considerable progress in the last 20 years, but graft-versus-host disease (GVHD) continues to be a major, life-threatening post-transplantation complication. Despite ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395G01N33/566
CPCA61K2039/505C07K16/24G01N2800/245G01N2030/8831G01N2333/523G01N33/6863A61P37/06A61K39/395
Inventor HORI, TSUKASAKOKAI, YASUONAISHIRO, YASUYOSHITSUTSUMI, HIROYUKIIMAI, KOHZOH
Owner SAPPORO MEDICAL UNIVERSITY